Financiere des Professionnels Fonds d investissement inc. Invests $619,000 in Mirum Pharmaceuticals, Inc. $MIRM

Financiere des Professionnels Fonds d investissement inc. acquired a new position in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 6,700 shares of the company’s stock, valued at approximately $619,000.

Several other large investors have also bought and sold shares of MIRM. Cullen Frost Bankers Inc. bought a new position in Mirum Pharmaceuticals in the fourth quarter valued at about $30,000. Eurizon Capital SGR S.p.A. bought a new position in shares of Mirum Pharmaceuticals in the fourth quarter worth about $32,000. CIBC Private Wealth Group LLC acquired a new stake in shares of Mirum Pharmaceuticals in the 4th quarter valued at approximately $32,000. Quantbot Technologies LP acquired a new stake in shares of Mirum Pharmaceuticals in the 3rd quarter valued at approximately $33,000. Finally, Comerica Bank grew its holdings in shares of Mirum Pharmaceuticals by 45.1% during the 1st quarter. Comerica Bank now owns 895 shares of the company’s stock valued at $40,000 after purchasing an additional 278 shares during the last quarter.

Analysts Set New Price Targets

A number of research firms recently issued reports on MIRM. Wolfe Research assumed coverage on shares of Mirum Pharmaceuticals in a research report on Tuesday, May 19th. They set an “outperform” rating and a $145.00 price objective for the company. Citigroup restated an “outperform” rating on shares of Mirum Pharmaceuticals in a research report on Monday, June 15th. Evercore reaffirmed an “outperform” rating and set a $138.00 target price on shares of Mirum Pharmaceuticals in a research note on Thursday, May 7th. Citizens Jmp upped their price target on shares of Mirum Pharmaceuticals from $140.00 to $146.00 and gave the stock a “market outperform” rating in a report on Monday, June 15th. Finally, TD Cowen increased their price target on Mirum Pharmaceuticals from $125.00 to $145.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Mirum Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $143.40.

Insider Buying and Selling

In related news, SVP Jolanda Howe sold 2,721 shares of Mirum Pharmaceuticals stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $120.00, for a total value of $326,520.00. Following the completion of the sale, the senior vice president owned 3,114 shares of the company’s stock, valued at approximately $373,680. This trade represents a 46.63% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Eric Bjerkholt sold 5,000 shares of the business’s stock in a transaction dated Monday, July 6th. The shares were sold at an average price of $122.25, for a total value of $611,250.00. Following the completion of the sale, the chief financial officer owned 42,181 shares in the company, valued at $5,156,627.25. This represents a 10.60% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 65,315 shares of company stock valued at $6,991,928. 8.32% of the stock is owned by insiders.

Mirum Pharmaceuticals Stock Up 1.3%

Mirum Pharmaceuticals stock opened at $118.86 on Friday. Mirum Pharmaceuticals, Inc. has a 1-year low of $50.25 and a 1-year high of $130.00. The company has a current ratio of 2.09, a quick ratio of 1.99 and a debt-to-equity ratio of 1.28. The firm’s fifty day moving average price is $107.97 and its two-hundred day moving average price is $99.09. The firm has a market capitalization of $7.25 billion, a price-to-earnings ratio of -8.73 and a beta of 0.48.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its quarterly earnings data on Wednesday, May 6th. The company reported ($13.43) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($12.68). The firm had revenue of $159.88 million for the quarter, compared to the consensus estimate of $148.21 million. Mirum Pharmaceuticals had a negative net margin of 140.24% and a negative return on equity of 11.28%. Mirum Pharmaceuticals’s revenue for the quarter was up 43.3% on a year-over-year basis. During the same period last year, the company posted ($0.30) earnings per share. On average, equities research analysts predict that Mirum Pharmaceuticals, Inc. will post -2.01 earnings per share for the current fiscal year.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.